Skip to main content

FDA Grants Breakthrough Therapy Designation to JNJ-6372 in Metastatic Non-Small Cell Lung Cancer

*March 2020*

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. It has been approved for people whose disease continues to grow either during or after receiving platinum-based chemotherapy. Read more.